|
|
Neurocognitive
sequelae in the treatment of low-grade gliomas
Taphoorn MJ
Department of Neurology/Neuro-Oncology G03.228, University
Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands.
Patients with low-grade gliomas may live without disease progression for many
years after initial diagnosis and treatment, but long-term cognitive deficits,
which affect up to 90% of patients, can have a sustained negative effect on
their daily functioning and quality of life.
Cognitive deficits in patients with low-grade gliomas may be caused by the tumor
itself or by various other factors including tumor-related epilepsy, tumor
treatment (surgery, radiotherapy [RT], medical therapy [including
chemotherapy]), psychological stress, or a combination of these.
Although some studies suggest a strong link between RT and neurocognitive
sequelae, other studies have found little evidence that RT is a major risk
factor for cognitive deficits and suggest that other factors may play a major
role.
The results of a recent cross-sectional study involving 195 patients with
low-grade gliomas (104 of whom received RT) strongly suggest that standard focal
RT with fractional doses less than 2 Gy is not generally associated with an
increased risk of cognitive deficits, but that higher fractional doses are
likely to result in cognitive disability.
Notably, the presence and severity of epileptic seizures and/or the use of
antiepileptic drugs were more strongly associated with cognitive deficits than
was RT.
This and other studies suggest that disease and treatment factors other than
standard focal RT may be more important with respect to increasing the risk of
neurocognitive sequelae in patients with low-grade gliomas.
PMID: 14765385 [PubMed - in process]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14765385&dopt=Abstract
|